Metropolis Healthcare Limited
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinic… Read more
Metropolis Healthcare Limited (METROPOLIS) - Net Assets
Latest net assets as of September 2025: ₹14.43 Billion INR
Based on the latest financial reports, Metropolis Healthcare Limited (METROPOLIS) has net assets worth ₹14.43 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹19.93 Billion) and total liabilities (₹5.49 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹14.43 Billion |
| % of Total Assets | 72.43% |
| Annual Growth Rate | 13.93% |
| 5-Year Change | 88.49% |
| 10-Year Change | 354.14% |
| Growth Volatility | 15.33 |
Metropolis Healthcare Limited - Net Assets Trend (2014–2025)
This chart illustrates how Metropolis Healthcare Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Metropolis Healthcare Limited (2014–2025)
The table below shows the annual net assets of Metropolis Healthcare Limited from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹13.35 Billion | +21.41% |
| 2024-03-31 | ₹10.99 Billion | +10.96% |
| 2023-03-31 | ₹9.91 Billion | +11.55% |
| 2022-03-31 | ₹8.88 Billion | +25.44% |
| 2021-03-31 | ₹7.08 Billion | +34.83% |
| 2020-03-31 | ₹5.25 Billion | +25.05% |
| 2019-03-31 | ₹4.20 Billion | -2.14% |
| 2018-03-31 | ₹4.29 Billion | +24.69% |
| 2017-03-31 | ₹3.44 Billion | +17.11% |
| 2016-03-31 | ₹2.94 Billion | -23.53% |
| 2015-03-31 | ₹3.84 Billion | +20.93% |
| 2014-03-31 | ₹3.18 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Metropolis Healthcare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 341.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹10.31 Billion | 77.49% |
| Common Stock | ₹103.60 Million | 0.78% |
| Other Comprehensive Income | ₹430.47 Million | 3.23% |
| Other Components | ₹2.46 Billion | 18.50% |
| Total Equity | ₹13.31 Billion | 100.00% |
Metropolis Healthcare Limited Competitors by Market Cap
The table below lists competitors of Metropolis Healthcare Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Create Technology & Science Co Ltd
SHE:000551
|
$557.14 Million |
|
Nanjing Kangni Mechanical & Electrical Co Ltd
SHG:603111
|
$557.19 Million |
|
Elkem ASA
OTCGREY:ELKEF
|
$557.68 Million |
|
Young & Co.'s Brewery P.L.C.
PINK:YCSBF
|
$557.84 Million |
|
Hunan Yussen Energy Technology
SHE:002986
|
$557.04 Million |
|
Sanhe Tongfei Refrigeration Co. Ltd.
SHE:300990
|
$556.64 Million |
|
Banca Farmafactoring S.p.A.
LSE:0RON
|
$556.56 Million |
|
Huayi Brothers Media Corp
SHE:300027
|
$556.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Metropolis Healthcare Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,961,555,000 to 13,309,720,000, a change of 2,348,165,000 (21.4%).
- Net income of 1,449,683,000 contributed positively to equity growth.
- Share repurchases of 102,000 reduced equity.
- New share issuances of 102,000 increased equity.
- Other comprehensive income increased equity by 17,404,000.
- Other factors increased equity by 881,078,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹1.45 Billion | +10.89% |
| Share Repurchases | ₹102.00K | -0.0% |
| Share Issuances | ₹102.00K | +0.0% |
| Other Comprehensive Income | ₹17.40 Million | +0.13% |
| Other Changes | ₹881.08 Million | +6.62% |
| Total Change | ₹- | 21.42% |
Book Value vs Market Value Analysis
This analysis compares Metropolis Healthcare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 31.53x to 7.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-03-31 | ₹58.94 | ₹1858.00 | x |
| 2015-03-31 | ₹70.54 | ₹1858.00 | x |
| 2016-03-31 | ₹54.95 | ₹1858.00 | x |
| 2017-03-31 | ₹64.69 | ₹1858.00 | x |
| 2018-03-31 | ₹83.10 | ₹1858.00 | x |
| 2019-03-31 | ₹83.66 | ₹1858.00 | x |
| 2020-03-31 | ₹103.80 | ₹1858.00 | x |
| 2021-03-31 | ₹138.11 | ₹1858.00 | x |
| 2022-03-31 | ₹172.36 | ₹1858.00 | x |
| 2023-03-31 | ₹192.38 | ₹1858.00 | x |
| 2024-03-31 | ₹213.28 | ₹1858.00 | x |
| 2025-03-31 | ₹258.48 | ₹1858.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Metropolis Healthcare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.89%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.89%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 1.40x
- Recent ROE (10.89%) is below the historical average (21.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 18.71% | 14.57% | 0.99x | 1.30x | ₹263.28 Million |
| 2015 | 16.85% | 13.39% | 0.98x | 1.28x | ₹247.91 Million |
| 2016 | 27.55% | 16.15% | 1.20x | 1.42x | ₹489.24 Million |
| 2017 | 31.46% | 18.66% | 1.06x | 1.59x | ₹693.40 Million |
| 2018 | 25.13% | 16.11% | 1.22x | 1.28x | ₹627.59 Million |
| 2019 | 28.71% | 15.78% | 1.38x | 1.32x | ₹782.94 Million |
| 2020 | 24.32% | 14.87% | 1.14x | 1.44x | ₹749.76 Million |
| 2021 | 25.91% | 18.35% | 0.99x | 1.42x | ₹1.12 Billion |
| 2022 | 24.17% | 17.44% | 0.80x | 1.73x | ₹1.26 Billion |
| 2023 | 14.46% | 12.44% | 0.76x | 1.52x | ₹440.59 Million |
| 2024 | 11.66% | 10.58% | 0.78x | 1.42x | ₹182.01 Million |
| 2025 | 10.89% | 10.89% | 0.71x | 1.40x | ₹118.71 Million |
Industry Comparison
This section compares Metropolis Healthcare Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $7,490,162,308
- Average return on equity (ROE) among peers: 16.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Metropolis Healthcare Limited (METROPOLIS) | ₹14.43 Billion | 18.71% | 0.38x | $557.10 Million |
| Krsnaa Diagnostics Limited (KRSNAA) | $6.69 Billion | 10.23% | 0.31x | $119.95 Million |
| Dr. Lal Path Labs Ltd. (LALPATHLAB) | $1.17 Billion | 38.19% | 0.51x | $1.16 Billion |
| SAI LIFE SCIENCES LTD (SAILIFE) | $8.88 Billion | 1.12% | 1.46x | $1.01 Billion |
| SURAKSHA (SURAKSHA) | $1.26 Billion | 5.10% | 0.36x | $27.40K |
| Syngene International Limited (SYNGENE) | $36.18 Billion | 12.84% | 0.61x | $834.43 Million |
| Thyrocare Technologies Limited (THYROCARE) | $1.02 Billion | 34.10% | 0.34x | $258.97 Million |
| Vijaya Diagnostic Centre Limited (VIJAYA) | $3.59 Billion | 23.52% | 0.51x | $530.99 Million |
| Vimta Labs Limited (VIMTALABS) | $1.12 Billion | 3.75% | 0.29x | $72.56 Million |